Daraxonrasib doubles survival — a RAS‑targeting drug development breakthrough.

Understanding how the human pancreas develops is crucial to allow scientists to make insulin producing–beta cells in the quest to cure type 1 diabetes. Now, scientists have made a unique and ...

Syntax Bio, a synthetic biology company programming next generation cell therapies, today announced a research and ...

Scientists at the Free University of Brussels (VUB) have taken a major step forward in pancreatic cancer research. By mapping ...

A surprising new study suggests that when it comes to pancreatic cancer, the kind of fat you eat may matter more than how ...

Nearly 98% of the human genome does not encode proteins but comprises noncoding sequences—the “dark genome”—such as regulatory sequences that control gene transcription (enhancer elements). Thousands ...

Hans Clevers, PhD, has been working on organoids from the beginning. He was group leader for twenty years at the Hubrecht Institute and has been head of pharma research and early development (pRED) of ...

For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic ...

At ASCO, Dr Shubham Pant discussed trial results showing Daraxonrasib improved outcomes in advanced pancreatic cancer. He ...

Pancreatic cancer is one of the deadliest forms of cancer. This is largely due to the cancer being detected at a late stage. In addition, treatment options for pancreatic cancer are limited. Therefore ...